【Pfizer China President: Continuing to Deepen Investment in the Chinese Market for the Next 5 Years】 Pfizer China President Jean-Christophe Pointeau (Peng Zhenke) stated in an exclusive interview that the 'Pfizer China 2030 Strategy' has three main components: first, accelerating the introduction of innovative drugs. Second, collaborating with the government and medical associations to improve disease diagnosis and treatment levels. Third, partnering with local biopharmaceutical companies to develop innovative products in China. The Chinese market is a strategic priority for Pfizer, and the rapid development of China's pharmaceutical and healthcare industry, the continuous improvement of medical insurance policies, and the accelerated drug approval system reform have all strengthened Pfizer's confidence in continuing to invest in the Chinese market. In the next five years, Pfizer will invest $1 billion in China. (Source: Jinshi Data)